Condition
Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07503353Phase 1Not Yet Recruiting
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
NCT01663766Phase 1Terminated
Phase I Study of Milatuzumab for Graft Versus Host Disease
Showing all 2 trials